ArticleBritish journal of cancer2026
Tumour deposits in colorectal carcinoma are associated with immune evasion and dose-dependent adverse prognosis beyond nodal status.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumour deposits (TDs) are established adverse prognostic features in colorectal carcinoma, yet their biologic significance and integration into current nodal staging systems remain controversial. Although TD burden has been associated with adverse prognosis beyond lymph node metastasis, its incremental staging relevance and the immune microenvironmental features of the primary tumour that may underlie the aggressive behaviour of TD-positive tumours remain incompletely defined.
methodsWe evaluated 845 consecutive colorectal carcinomas resected at a single institution between 2007 and 2015. Clinicopathologic features, TD burden and disease-specific survival (DSS) were analysed. Immune profiling was performed on tissue microarrays using immunohistochemistry for CD8, CD163, FoxP3, LAG3, PD-L1, HLA class I, HLA class II, and beta-2-microglobulin (B2M), with automated quantitative image analysis.
resultsAmong 825 patients with available data, TDs were identified in 106 cases (12.8%) and were significantly associated with adverse clinicopathologic features, including advanced T stage, lymph node metastasis, extramural venous invasion, perineural invasion, and distant metastasis. TD-positive tumours demonstrated significantly worse 5-year DSS compared with TD-negative tumours (45.8 vs. 81.0%, p < 0.001). Increasing TD burden conferred a dose-dependent adverse impact on DSS (p < 0.001), including within lymph node-positive disease. Within stage III tumours, TD burden stratified outcome beyond conventional nodal categories with pN1 tumours lacking TDs approximating stage II survival and pN2 tumours with TDs approaching stage IV outcomes. In this context, TD-positive tumours showed reduced intratumoral CD8+ T-cell infiltration, decreased tumour cell B2M expression and increased tumour cell PD-L1 expression, consistent with an immune-evasive phenotype.
conclusionsTDs are associated with adverse clinicopathologic features, immune-evasive tumour microenvironments and poor disease-specific survival in colorectal carcinoma. Quantitative TD burden provides additional prognostic information beyond nodal status, supporting the incorporation of TD burden into future staging paradigms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.